BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed INAB catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:89149df8b8cbd3cc737e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:INAB P1/P2 readout (est.): A Phase 1b / 2 Drug Resistant Immunother
 apy With Activated\, Gene Modified Allogeneic or Autologous γδ T Cells (
 DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recu
 rrent or Newly Diagnosed Glioblastoma
DESCRIPTION:A Phase 1b / 2 Drug Resistant Immunotherapy With Activated\, Ge
 ne Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination 
 With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnose
 d Glioblastoma\nNCT05664243 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | spon
 sor: In8bio Inc.\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nDate precision: month (shown on the first day)\nTick
 er INAB (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0566
 4243\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05664243
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
